Referências

1. Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study, Arthritis Rheumatol, 66, 11, pp. 3096-3104, (2014)
2. Aikawa N.E., Sallum A.M., Pereira R.M., Suzuki L., Viana V.S., Bonfa E., Et al., Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy, Clin Exp Rheumatol, 30, 3, pp. 445-449, (2012)
3. Alshaiki F., Obaid E., Almuallim A., Taha R., El-Haddad H., Almoallim H., Outcomes of rituximab therapy in refractory lupus: A meta-analysis, Eur J Rheumatol, 5, 2, pp. 118-126, (2018)
4. Anders H.-J., Saxena R., Zhao M.-H., Parodis I., Salmon J.E., Mohan C., Lupus nephritis, Nat Rev Dis Primers, 6, 1, (2020)
5. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., Et al., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis, J Am Soc Nephrol, 20, 5, pp. 1103-1112, (2009)
6. Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Et al., 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Arthritis Rheum, 71, 9, pp. 1400-1412, (2019)
7. Arkin L.M., Nguyen C., Klein-Gitelman M., Cutaneous manifestations of pediatric lupus, Curr Opin Rheumatol, 31, 5, pp. 411-420, (2019)
8. Aronoff G.R., Bennett W.M., Berns J.S., Brier M.E., Kasbekar N., Mueller B.A., Et al., Drug prescribing in renal failure: Dosing guidelines for adults and children, (2007)
9. Austin H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., Et al., Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med, 314, 10, pp. 614-619, (1986)
10. Austin H.A., Illei G.G., Braun M.J., Balow J.E., Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy, J Am Soc Nephrol, 20, 4, pp. 901-911, (2009)
11. Avcin T., Cimaz R., Rozman B., The ped-APS registry: The antiphospholipid syndrome in childhood, Lupus, 18, 10, pp. 894-899, (2009)
12. Bajema I.M., Wilhelmus S., Alpers C.E., Bruijn J.A., Colvin R.B., Cook H.T., Et al., Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices, Kidney Int, 93, 4, pp. 789-796, (2018)
13. Ballestar E., Sawalha A.H., Lu Q., Clinical value of DNA methylation markers in autoimmune rheumatic diseases, Nat Rev Rheumatol, 16, 9, pp. 514-524, (2020)
14. Bao H., Liu Z.H., Xie H.L., Hu W.X., Zhang H.T., Li L.S., Successful treatment of class V+IV lupus nephritis with multitarget therapy, J Am Soc Nephrol, 19, 10, pp. 2001-2010, (2008)
15. Barbhaiya M., Costenbader K.H., Environmental exposures and the development of systemic lupus erythematosus, Curr Opin Rheumatol, 28, 5, pp. 497-505, (2016)
16. Bartosh S.M., Fine R.N., Sullivan E.K., Outcome after transplantation of young patients with systemic lupus erythematosus: A report of the North American pediatric renal transplant cooperative study, Transplantation, 72, 5, pp. 973-978, (2001)
17. Bensman A., Niaudet P., Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies, Pediatr Nephrol, 25, 7, pp. 1197-1199, (2010)
18. Berman H., Rodriguez-Pinto I., Cervera R., Gregory S., de Meis E., Rodrigues C.E., Et al., Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the “CAPS Registry”, Autoimmun Rev, 13, 2, pp. 157-162, (2014)
19. Boneparth A., Davidson A., B-cell activating factor targeted therapy and lupus, Arthritis Res Ther, 14, (2012)
20. Boneparth A., Ilowite N., Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: A cross-sectional analysis of the CARRA Registry, Lupus, 23, 9, pp. 898-904, (2014)
21. Brasileiro A., Fonseca Oliveira J., Pinheiro S., Paiva-Lopes M.J., Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin, Lupus, 25, 6, pp. 663-665, (2016)
22. Broder A., Khattri S., Patel R., Putterman C., Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality, J Rheumatol, 38, 11, pp. 2382-2389, (2011)
23. Brunner H.I., Klein-Gitelman M.S., Higgins G.C., Lapidus S.K., Levy D.M., Eberhard A., Et al., Toward the development of criteria for global flares in juvenile systemic lupus erythematosus, Arthritis Care Res, 62, 6, pp. 811-820, (2010)
24. Brunner H.I., Bennett M., Abulaban K., Klein-Gitelman M., O'Neil K., Tucker L., Et al., Development of a novel renal activity index of lupus nephritis in children and young adults, Arthritis Care Res, 68, 7, pp. 1003-1011, (2016)
25. Brunner H.I., Gulati G., Klein-Gitelman M.S., Rouster-Stevens K.A., Tucker L., Ardoin S.P., Et al., Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus, Pediatr Nephrol, 34, 1, pp. 117-128, (2018)
26. Brunner H.I., Holland M., Beresford M.W., Ardoin S.P., Appenzeller S., Silva C.A., Et al., American college of rheumatology provisional criteria for global flares in childhood-onset systemic lupus erythematosus, Arthritis Care Res, 70, 6, pp. 813-822, (2018)
27. Bundhun P.K., Kumari A., Huang F., Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: A systematic review and meta-analysis, Medicine, 96, 37, (2017)
28. Buyon J.P., Kim M.Y., Copel J.A., Friedman D.M., Anti-Ro/SSA antibodies and congenital heart block: Necessary but not sufficient, Arthritis Rheum, 44, 8, pp. 1723-1727, (2001)
29. Carter E.E., Barr S.G., Clarke A.E., The global burden of SLE: Prevalence, health disparities and socioeconomic impact, Nat Rev, 12, 10, pp. 605-620, (2016)
30. Chang A., Henderson S.G., Brandt D., Liu N., Guttikonda R., Hsieh C., Et al., In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis, J Immunol, 186, 3, pp. 1849-1860, (2011)
31. Chang Y.S., Liu C.J., Wu T.H., Chaou C.H., Lin K.C., Ou S.M., Et al., Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: A nationwide population-based study in Taiwan, Rheumatology, 52, 1, pp. 166-172, (2013)
32. Chen W., Liu Q., Tang X., Fu P., Liu F., Liao Y., Et al., Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: A multicenter randomized clinical trial, Lupus, 21, 9, pp. 944-952, (2012)
33. Churg J., Bernstein J., Glassock R.J., Renal disease: Classification and atlas of glomerular diseases, (1995)
34. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., Et al., Sequential therapies for proliferative lupus nephritis, N Engl J Med, 350, 10, pp. 971-980, (2004)
35. Contreras G., Mattiazzi A., Guerra G., Ortega L.M., Tozman E.C., Li H., Et al., Recurrence of lupus nephritis after kidney transplantation, J Am Soc Nephrol, 21, 7, pp. 1200-1207, (2010)
36. Cortes-Hernandez J., Torres-Salido M.T., Medrano A.S., Tarres M.V., Ordi-Ros J., Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases, Nephrol Dial Transplant, 25, 12, pp. 3939-3948, (2010)
37. Costa-Reis P., Sullivan K.E., Monogenic lupus: It’s all new!, Curr Opin Immunol, 49, pp. 87-95, (2017)
38. Crispin J.C., Kyttaris V.C., Terhorst C., Tsokos G.C., T cells as therapeutic targets in SLE, Nat Rev, 6, 6, pp. 317-325, (2010)
39. Dang J., Shan S., Li J., Zhao H., Xin Q., Liu Y., Et al., Gene-gene interactions of IRF5, STAT4, IKZF1 and ETS1 in systemic lupus erythematosus, Tissue Antigens, 83, 6, pp. 401-408, (2014)
40. de Araujo D.B., Yamakami L.Y., Aikawa N.E., Bonfa E., Viana V.S., Pasoto S.G., Et al., Ovarian reserve in adult patients with childhood-onset lupus: A possible deleterious effect of methotrexate?, Scand J Rheumatol, 43, 6, pp. 503-511, (2014)
41. Dooley M.A., Cosio F.G., Nachman P.H., Falkenhain M.E., Hogan S.L., Falk R.J., Et al., Mycophenolate mofetil therapy in lupus nephritis: Clinical observations, J Am Soc Nephrol, 10, 4, pp. 833-839, (1999)
42. Dooley M.A., Jayne D., Ginzler E.M., Isenberg D., Olsen N.J., Wofsy D., Et al., Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis, N Engl J Med, 365, 20, pp. 1886-1895, (2011)
43. Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Et al., 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis, (2019)
44. Fernandez M., Alarcon G.S., Calvo-Alen J., Andrade R., McGwin G., Vila L.M., Et al., A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE, Arthritis Rheum, 57, 4, pp. 576-584, (2007)
45. Furie R., Rovin B.H., Houssiau F., Malvar A., Teng Y.K.O., Contreras G., Et al., Two-year, randomized, controlled trial of belimumab in lupus nephritis, N Engl J Med, 383, 12, pp. 1117-1128, (2020)
46. Galbraith L., Manns B., Hemmelgarn B., Walsh M., The steroids in the maintenance of remission of proliferative lupus nephritis (SIMPL) pilot trial, Can J Kidney Health Dis, 1, (2014)
47. Gawdat G., El-Fayoumi D., Marzouk H., Farag Y., Ocular manifestations in children with juvenileonset systemic lupus erythematosus, Semin Ophthalmol, 33, 4, pp. 470-476, (2018)
48. Gedalia A., Molina J.F., Molina J., Uribe O., Malagon C., Espinoza L.R., Childhood-onset systemic lupus erythematosus: A comparative study of African Americans and Latin Americans, J Natl Med Assoc, 91, 9, pp. 497-501, (1999)
49. Gibson K.L., Gipson D.S., Massengill S.A., Dooley M.A., Primack W.A., Ferris M.A., Et al., Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: Focus on children, adolescents, and young adults, Clin J Am Soc Nephrol, 4, 12, pp. 1962-1967, (2009)
50. Gomez Mendez L.M., Cascino M.D., Garg J., Katsumoto T.R., Brakeman P., Dall'Era M., Et al., Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis, Clin J Am Soc Nephrol, 13, 10, pp. 1502-1509, (2018)
51. Groot N., de Graeff N., Marks S.D., Brogan P., Avcin T., Bader-Meunier B., Et al., European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: The SHARE initiative, Ann Rheum Dis, 76, 12, pp. 1965-1973, (2017)
52. Groot N., Graeff N., Avcin T., Bader-Meunier B., Brogan P., Dolezalova P., Et al., European evidencebased recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative, Ann Rheum Dis, 76, 11, pp. 1788-1796, (2017)
53. Grootscholten C., Ligtenberg G., Hagen E.C., van den Wall Bake A.W., de Glas-Vos J.W., Bijl M., Et al., Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial, Kidney Int, 70, 4, pp. 732-742, (2006)
54. Guariento A., Silva M.F., Tassetano P.S., Rocha S.M., Campos L.M., Valente M., Et al., Liver and spleen biometrics in childhood-onset systemic lupus erythematosus patients, Rev Bras Reumatol, 55, 4, pp. 346-351, (2015)
55. Gutierrez-Suarez R., Ruperto N., Gastaldi R., Pistorio A., Felici E., Burgos-Vargas R., Et al., A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index based on the analysis of 1, 015 patients with juvenile-onset systemic lupus erythematosus, Arthritis Rheum, 54, 9, pp. 2989-2996, (2006)
56. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., Et al., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care Res, 64, 6, pp. 797-808, (2012)
57. Harrison M.J., Zuhlke L.J., Lewandowski L.B., Scott C., Pediatric systemic lupus erythematosus patients in South Africa have high prevalence and severity of cardiac and vascular manifestations, Pediatr Rheumatol Online J, 17, 1, (2019)
58. Hartman E.A.R., van Royen-Kerkhof A., Jacobs J.W.G., Welsing P.M.J., Fritsch-Stork R.D.E., Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-analysis, Autoimmun Rev, 17, 3, pp. 316-322, (2018)
59. Heshin-Bekenstein M., Trupin L., Yelin E., von Scheven E., Yazdany J., Lawson E.F., Longitudinal disease-and steroid-related damage among adults with childhood-onset systemic lupus erythematosus, Semin Arthritis Rheum, 49, 2, pp. 267-272, (2019)
60. Hill G.S., Delahousse M., Nochy D., Tomkiewicz E., Remy P., Mignon F., Et al., A new morphologic index for the evaluation of renal biopsies in lupus nephritis, Kidney Int, 58, 3, pp. 1160-1173, (2000)
61. Hiraki L.T., Benseler S.M., Tyrrell P.N., Harvey E., Hebert D., Silverman E.D., Ethnic differences in pediatric systemic lupus erythematosus, J Rheumatol, 36, 11, pp. 2539-2546, (2009)
62. Hiraki L.T., Lu B., Alexander S.R., Shaykevich T., Alarcon G.S., Solomon D.H., Et al., End-stage renal disease due to lupus nephritis among children in the US, 1995-2006, Arthritis Rheum, 63, 7, pp. 1988-1997, (2011)
63. Hochberg M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 40, 9, (1997)
64. Holland M.J., Beresford M.W., Feldman B.M., Huggins J., Norambuena X., Silva C.A., Et al., Measuring disease damage and its severity in childhood-onset systemic lupus erythematosus, Arthritis Care Res, (2018)
65. Houssiau F.A., D'Cruz D., Sangle S., Remy P., Vasconcelos C., Petrovic R., Et al., Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial, Ann Rheum Dis, 69, 12, pp. 2083-2089, (2010)
66. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon G.E., Danieli M.G., Et al., The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide, Ann Rheum Dis, 69, 1, pp. 61-64, (2010)
67. Hu W., Chen Y., Wang S., Chen H., Liu Z., Zeng C., Et al., Clinical-morphological features and outcomes of lupus podocytopathy, Clin J Am Soc Nephrol, 11, 4, pp. 585-592, (2016)
68. Islabao A., Mota L., Ribeiro M., Arabi T., Cividatti G., Queiroz L., Et al., Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1, 519 patients, Autoimmun Rev, 19, 12, (2020)
69. Jarrot P.A., Chiche L., Hervier B., Daniel L., Vuiblet V., Bardin N., Et al., Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis, Medicine, 95, 22, (2016)
70. Jesus A.A., Liphaus B.L., Silva C.A., Bando S.Y., Andrade L.E., Coutinho A., Et al., Complement and antibody primary immunodeficiency in juvenile systemic lupus erythematosus patients, Lupus, 20, 12, pp. 1275-1284, (2011)
71. Kamanamool N., McEvoy M., Attia J., Ingsathit A., Ngamjanyaporn P., Thakkinstian A., Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: Systematic review and meta-analysis, Medicine, 89, 4, pp. 227-235, (2010)
72. Kamphuis S., Silverman E.D., Prevalence and burden of pediatric-onset systemic lupus erythematosus, Nat Rev, 6, 9, pp. 538-546, (2010)
73. Kanda H., Kubo K., Tateishi S., Sato K., Yonezumi A., Yamamoto K., Et al., Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy, Lupus, 14, 4, pp. 288-292, (2005)
74. Kang S.H., Chung B.H., Choi S.R., Lee J.Y., Park H.S., Sun I.O., Et al., Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis, Korean J Intern Med, 26, 1, pp. 60-67, (2011)
75. Kapitsinou P.P., Boletis J.N., Skopouli F.N., Boki K.A., Moutsopoulos H.M., Lupus nephritis: Treatment with mycophenolate mofetil, Rheumatology, 43, 3, pp. 377-380, (2004)
76. Karasawa K., Uchida K., Kodama M., Moriyama T., Nitta K., Long-term effects of tacrolimus for maintenance therapy of lupus nephritis: A 5-year retrospective study at a single center, Rheumatol Int, 38, 12, pp. 2271-2277, (2018)
77. Kavanaugh A.F., Solomon D.H., Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNAantibody tests, Arthritis Rheum, 47, 5, pp. 546-555, (2002)
78. KDIGO Clinical practice guideline for glomerulonephritis: Lupus nephritis, Kidney Inter Suppl, 2, pp. 90-101, (2012)
79. Knight A., Kogon A.J., Matheson M.B., Warady B.A., Furth S.L., Hooper S.R., Cognitive function in children with lupus nephritis: A cross-sectional comparison with children with other glomerular chronic kidney diseases, J Pediatr, (2017)
80. Kohler J.A., Ellis A.R., Libman-Sacks endocarditis in pediatric patient with systemic lupus erythematosus, Pediatr Cardiol, 33, 8, pp. 1466-1468, (2012)
81. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., Rohde R.D., Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group, Am J Kidney Dis, 35, 5, pp. 904-914, (2000)
82. Krishnan M.R., Wang C., Marion T.N., Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice, Kidney Int, 82, 2, pp. (*)([A-z]), (2012)
83. Lee K.H., Lee H., Lee C.H., Kim J.Y., Kim J.M., Kim S.S., Et al., Adrenal insufficiency in systematic lupus erythematosus (SLE) and antiphospholipid syndrome (APS): A systematic review, Autoimmun Rev, 18, 1, pp. 1-8, (2019)
84. Lehman T.J., Onel K., Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus, J Pediatr, 136, 2, pp. 243-247, (2000)
85. Leuchten N., Hoyer A., Brinks R., Schoels M., Schneider M., Smolen J., Et al., Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data, Arthritis Care Res, 70, 3, pp. 428-438, (2018)
86. Levy D.M., Peschken C.A., Tucker L.B., Chedeville G., Huber A.M., Pope J.E., Et al., Influence of ethnicity on childhood-onset systemic lupus erythematosus: Results from a multiethnic multicenter Canadian cohort, Arthritis Care Res, 65, 1, pp. 152-160, (2013)
87. Lewandowski L.B., Schanberg L.E., Thielman N., Phuti A., Kalla A.A., Okpechi I., Et al., Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa, Lupus, (2016)
88. Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D., Lachin J.M., A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group, N Engl J Med, 326, 21, pp. 1373-1379, (1992)
89. Li X., Ren H., Zhang Q., Zhang W., Wu X., Xu Y., Et al., Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis, Nephrol Dial Transplant, 27, 4, pp. 1467-1472, (2012)
90. Li W., Titov A.A., Morel L., An update on lupus animal models, Curr Opin Rheumatol, 29, 5, pp. 434-441, (2017)
91. Lin W.Y., Chang C.L., Fu L.S., Lin C.H., Lin H.K., Systemic lupus erythematosus and thyroid disease: A 10-year study, J Microbiol Immunol Infect, 48, 6, pp. 676-683, (2015)
92. Liu Z., Zhang H., Liu Z., Xing C., Fu P., Ni Z., Et al., Multitarget therapy for induction treatment of lupus nephritis: A randomized, controlled trial, Ann Intern Med, 162, 1, pp. 18-26, (2015)
93. Llanos C., Izmirly P.M., Katholi M., Clancy R.M., Friedman D.M., Kim M.Y., Et al., Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors, Arthritis Rheum, 60, 10, pp. 3091-3097, (2009)
94. Lood C., Blanco L.P., Purmalek M.M., Carmona-Rivera C., De Ravin S.S., Smith C.K., Et al., Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease, Nat Med, 22, 2, pp. 146-153, (2016)
95. MacIsaac J., Siddiqui R., Jamula E., Li N., Baker S., Webert K.E., Et al., Systematic review of rituximab for autoimmune diseases: A potential alternative to intravenous immune globulin, Transfusion, 58, 11, pp. 2729-2735, (2018)
96. Mackay M., Dall'Era M., Fishbein J., Kalunian K., Lesser M., Sanchez Guerrero J., Et al., Establishing surrogate kidney endpoints for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes, Arthritis Rheumatol, 71, 3, pp. 411-419, (2018)
97. Mahajan A., Amelio J., Gairy K., Kaur G., Levy R.A., Roth D., Et al., Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression, Lupus, (2020)
98. Maroz N., Segal M.S., Lupus nephritis and end-stage kidney disease, Am J Med Sci, 346, 4, pp. 319-323, (2013)
99. McMurray R.W., May W., Sex hormones and systemic lupus erythematosus: Review and meta-analysis, Arthritis Rheum, 48, 8, pp. 2100-2110, (2003)
100. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., Et al., The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans, J Clin Invest, 121, 9, pp. 3635-3644, (2011)
101. Midgley A., Beresford M.W., Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity, Lupus, 25, 4, pp. 407-411, (2016)
102. Mina R., Brunner H.I., Update on differences between childhood-onset and adult-onset systemic lupus erythematosus, Arthritis Res Ther, 15, 4, (2013)
103. Mina R., von Scheven E., Ardoin S.P., Eberhard B.A., Punaro M., Ilowite N., Et al., Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus, Arthritis Care Res, 64, 3, pp. 375-383, (2012)
104. Mok C.C., Calcineurin inhibitors in systemic lupus erythematosus, Best Pract Res, 31, 3, pp. 429-438, (2017)
105. Mok C.C., Ying K.Y., Yim C.W., Ng W.L., Wong W.S., Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine, Lupus, 18, 12, pp. 1091-1095, (2009)
106. Mok C.C., Ying K.Y., Yim C.W., Siu Y.P., Tong K.H., To C.H., Et al., Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up, Ann Rheum Dis, 75, 1, pp. 30-36, (2016)
107. Moroni G., Maccario M., Banfi G., Quaglini S., Ponticelli C., Treatment of membranous lupus nephritis, Am J Kidney Dis, 31, 4, pp. 681-686, (1998)
108. Moroni G., Quaglini S., Gravellone L., Gallelli B., Leoni A., Messa P., Et al., Membranous nephropathy in systemic lupus erythematosus: Long-term outcome and prognostic factors of 103 patients, Semin Arthritis Rheum, (2012)
109. Moroni G., Raffiotta F., Trezzi B., Giglio E., Mezzina N., Del Papa N., Et al., Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study, Rheumatology, (2014)
110. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Et al., Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial, Lancet, 377, 9767, pp. 721-731, (2011)
111. Niewold T.B., Swedler W.I., Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C, Clin Rheumatol, 24, 2, pp. 178-181, (2005)
112. Novak G.V., Molinari B.C., Ferreira J.C., Sakamoto A.P., Terreri M.T., Pereira R.M.R., Et al., Characteristics of 1555 childhood-onset lupus in three groups based on distinct time intervals to disease diagnosis: A Brazilian multicenter study, Lupus, (2018)
113. Orbach H., Tishler M., Shoenfeld Y., Intravenous immunoglobulin and the kidney-a two-edged sword, Semin Arthritis Rheum, 34, 3, pp. 593-601, (2004)
114. Pakchotanon R., Gladman D.D., Su J., Urowitz M.B., More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus, J Rheumatol, 45, 1, pp. 90-94, (2018)
115. Palmer S.C., Tunnicliffe D.J., Singh-Grewal D., Mavridis D., Tonelli M., Johnson D.W., Et al., Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network meta-analysis of randomized trials, Am J Kidney Dis, 70, 3, pp. 324-336, (2017)
116. Parodis I., Tamirou F., Houssiau F.A., Prediction of prognosis and renal outcome in lupus nephritis, Lupus Sci Med, 7, 1, (2020)
117. Paupitz J.A., Lima G.L., Alvarenga J.C., Oliveira R.M., Bonfa E., Pereira R.M., Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus, Osteoporos Int, 27, 5, pp. 1839-1848, (2016)
118. Pereira T., Abitbol C.L., Seeherunvong W., Katsoufis C., Chandar J., Freundlich M., Et al., Three decades of progress in treating childhood-onset lupus nephritis, Clin J Am Soc Nephrol, 6, 9, pp. 2192-2199, (2011)
119. Pereira M., Muscal E., Eldin K., Hicks M.J., Sagcal-Gironella A.C.P., DeGuzman M., Et al., Clinical presentation and outcomes of childhood-onset membranous lupus nephritis, Pediatr Nephrol, 32, 12, pp. 2283-2291, (2017)
120. Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., Et al., Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 64, 8, pp. 2677-2686, (2012)
121. Radeke H.H., Janssen-Graalfs I., Sowa E.N., Chouchakova N., Skokowa J., Loscher F., Et al., Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis, J Biol Chem, 277, 30, pp. 27535-27544, (2002)
122. Radhakrishnan J., Kunis C.L., D'Agati V., Appel G.B., Cyclosporine treatment of lupus membranous nephropathy, Clin Nephrol, 42, 3, pp. 147-154, (1994)
123. Radhakrishnan J., Moutzouris D.A., Ginzler E.M., Solomons N., Siempos I.I., Appel G.B., Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis, Kidney Int, 77, 2, pp. 152-160, (2010)
124. Richardson A.E., Warrier K., Vyas H., Respiratory complications of the rheumatological diseases in childhood, Arch Dis Child, 101, 8, pp. 752-758, (2016)
125. Rijnink E.C., Teng Y.K.O., Wilhelmus S., Almekinders M., Wolterbeek R., Cransberg K., Et al., Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis, Clin J Am Soc Nephrol, 12, 5, pp. 734-743, (2017)
126. Rivera F., Merida E., Illescas M.L., Lopez-Rubio E., Frutos M.A., Garcia-Frias P., Et al., Mycophenolate in refractory and relapsing lupus nephritis, Am J Nephrol, 40, 2, pp. 105-112, (2014)
127. Rodrigues Fonseca A., Felix Rodrigues M.C., Sztajnbok F.R., Gerardin Poirot Land M., Knupp Feitosa de Oliveira S., Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus, Adv Rheumatol, 59, 1, (2019)
128. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., Et al., Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study, Arthritis Rheum, 64, 4, pp. 1215-1226, (2012)
129. Rovin B.H., Caster D.J., Cattran D.C., Gibson K.L., Hogan J.J., Moeller M.J., Et al., Management and treatment of glomerular diseases (part 2): Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference, Kidney Int, 95, 2, pp. 281-295, (2019)
130. Rovin B.H., Solomons N., Pendergraft W.F., Dooley M.A., Tumlin J., Romero-Diaz J., Et al., A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis, Kidney Int, 95, 1, pp. 219-231, (2019)
131. Rubinstein T.B., Mowrey W.B., Ilowite N.T., Wahezi D.M., Delays to care in pediatric lupus patients: Data from the childhood arthritis and rheumatology research alliance legacy registry, Arthritis Care Res, 70, 3, pp. 420-427, (2018)
132. Rubtsova K., Marrack P., Rubtsov A.V., Sexual dimorphism in autoimmunity, J Clin Invest, 125, 6, pp. 2187-2193, (2015)
133. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A., Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review, Ann Rheum Dis, 69, 1, pp. 20-28, (2010)
134. Ruiz-Irastorza G., Ugarte A., Saint-Pastou Terrier C., Lazaro E., Iza A., Couzi L., Et al., Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts, Autoimmun Rev, 16, 8, pp. 826-832, (2017)
135. Sahin S., Adrovic A., Barut K., Canpolat N., Ozluk Y., Kilicaslan I., Et al., Juvenile systemic lupus erythematosus in Turkey: Demographic, clinical and laboratory features with disease activity and outcome, Lupus, 27, 3, pp. 514-519, (2018)
136. Samuelson E.M., Laird R.M., Papillion A.M., Tatum A.H., Princiotta M.F., Hayes S.M., Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice, PLoS One, 9, 3, (2014)
137. Santiago A., Satriano J., DeCandido S., Holthofer H., Schreiber R., Unkeless J., Et al., A specific Fc gamma receptor on cultured rat mesangial cells, J Immunol, 143, 8, pp. 2575-2582, (1989)
138. Sawai T., Uzuki M., Satoh N., Kidney disease in systemic lupus erythematosus (SLE) of children-morphometric analysis of kidneys from autopsy cases, Tohoku J Exp Med, 177, 2, pp. 139-151, (1995)
139. Schanberg L.E., Sandborg C., Barnhart H.X., Ardoin S.P., Yow E., Evans G.W., Et al., Use of atorvastatin in systemic lupus erythematosus in children and adolescents, Arthritis Rheum, 64, 1, pp. 285-296, (2012)
140. Setoue D.N., Pitta A.C., Fiorot F.J., Nastri M.M., Novak G.V., Molinari B.C., Et al., Symptomatic polyautoimmunity at diagnosis of 1463 childhood-onset lupus: A Brazilian multicenter study, Autoimmun Rev, 17, 8, pp. 836-839, (2018)
141. Shafi S.T., Gupta M., Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis, J Vasc Access, 8, 2, pp. 103-108, (2007)
142. Silva C.A., Aikawa N.E., Pereira R.M., Campos L.M., Management considerations for childhoodonset systemic lupus erythematosus patients and implications on therapy, Expert Rev Clin Immunol, 12, 3, pp. 301-313, (2016)
143. Silverman G.J., Azzouz D.F., Alekseyenko A.V., Systemic lupus erythematosus and dysbiosis in the microbiome: Cause or effect or both?, Curr Opin Immunol, 61, pp. 80-85, (2019)
144. Singla S., Canter D.L., Vece T.J., Muscal E., DeGuzman M., Diffuse alveolar hemorrhage as a manifestation of childhood-onset systemic lupus erythematosus, Hosp Pediatr, 6, 8, pp. 496-500, (2016)
145. Smith E., Al-Abadi E., Armon K., Bailey K., Ciurtin C., Davidson J., Et al., Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis, Lupus, 28, 5, pp. 613-620, (2019)
146. Smith E.M.D., Lythgoe H., Midgley A., Beresford M.W., Hedrich C.M., Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options, Clin Immunol, 209, (2019)
147. Soares P.M., Borba E.F., Bonfa E., Hallak J., Correa A.L., Silva C.A., Gonad evaluation in male systemic lupus erythematosus, Arthritis Rheum, 56, 7, pp. 2352-2361, (2007)
148. Sonmez H.E., Karhan A.N., Batu E.D., Bilginer Y., Gumus E., Demir H., Et al., Gastrointestinal system manifestations in juvenile systemic lupus erythematosus, Clin Rheumatol, 36, 7, pp. 1521-1526, (2017)
149. Sopena B., Rivera A., Chamorro A., Freire M., Alende V., Seco E., Et al., Clinical association between Kikuchi’s disease and systemic lupus erythematosus: A systematic literature review, Semin Arthritis Rheum, 47, 1, pp. 46-52, (2017)
150. Sousa S., Goncalves M.J., Ines L.S., Eugenio G., Jesus D., Fernandes S., Et al., Clinical features and long-term outcomes of systemic lupus erythematosus: Comparative data of childhood, adult and late-onset disease in a national register, Rheumatol Int, 36, 7, pp. 955-960, (2016)
151. Soybilgic A., Tesher M., Wagner-Weiner L., Onel K.B., A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America, Pediatr Rheumatol Online J, 12, (2014)